Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis

Table 1

Characteristics of the included cohort studies.

Study	Country	Design	Patient characteristics	Sample size	Mean age (years)	Male (%)	ICIs used	Definition of statin use	Number of statin users	Outcomes reported	Variables adjusted
Omori et al. [23]	Japan		Advanced NSCLC	67	67	69	Nivolumab	Concomitant statin evidenced by the medical records	10	PFS and OS	None
Svaton et al. [24]	Czech	R	Advanced NSCLC	224	67	59	Nivolumab	Concomitant statin evidenced by the medical records	31	PFS and OS	Age, sex, PS, smoking, histologic type, cancer stage, and concurrent medications
Rossi et al. [28]	Italy	R	Metastatic NSCLC	122	71	65	Nivolumab, pembrolizumab, or atezolizumab	Concomitant statin evidenced by the medical records	70	PFS and OS	None
Cantini et al. [25]	Italy	R	Advanced NSCLC	179	67	72	Nivolumab or pembrolizumab	Concomitant statin evidenced by the medical records	39	PFS and OS	Age, sex, smoking, PS, and histologic type
Kostine et al. [15]	France	R	Advanced NSCLC	150	65	70	PD-1/PD-L1 and/or CTLA4 inhibitors	Concomitant statin evidenced by the medical records	32	PFS and OS	None
Cortellini et al. [26]	Italy	R	Metastatic NSCLC	950	70	66	Pembrolizumab	Concomitant statin evidenced by the medical records	252	PFS and OS	None
Miura et al. [27]	Japan	R	Metastatic NSCLC	300	65	75	Nivolumab or pembrolizumab	Concomitant statin evidenced by the medical records	26	PFS and OS	Age, sex, PS, histologic type, previous therapy, and concurrent medications
Takada et al. [29]	Japan	R	Advanced or recurrent NSCLC	390	67	79	Nivolumab or pembrolizumab	Concomitant statin evidenced by the medical records	53	PFS and OS	Age, sex, PS, cancer stage, histologic type, mutational status, and BMI

ICIs, immune checkpoint inhibitors; P, prospective; R, retrospective; NSCLC, nonsmall cell lung cancer; PD-1/PD-LI, programmed death-1/ligand-1; CTLA4, cytotoxic T-lymphocyte associated protein 4; PFS, progression-free survival; OS, overall survival; PS, performance status; BMI, body mass index.